Hot on the heels of discovering a protective form of immune response to spinal cord injury, researchers at the University of Virginia School of Medicine have pinpointed the biological trigger for that response, a vital step toward being able to harness the body’s defenses to improve treatment for spine injuries, brain trauma, Alzheimer’s disease and other neurodegenerative conditions.
The trigger for the immune response, the molecule interleukin-33, is concentrated in what is known as white matter in the healthy brain and spinal cord. Interleukin-33, the researchers have discovered, is released upon injury and activates cells called glia, beginning the body’s protective response and promoting recovery. It’s the first thing that tells the immune system that something’s been damaged. It’s how the immune system initially knows to respond.
The researchers aren’t sure if interleukin-33 has other roles to play in addition to its role in injury response. Interleukin-33 must be important to the central nervous system. It is expressed all the time, even in the healthy state, and we’ve only described its activity after injury. From an evolutionary perspective it makes little sense. The system produces this constantly just in case of injury that may never come? The team feel there must be another function beyond injury. IL-33 may represent a language through which CNS is constantly talking with the immune system, or, in other words, a molecular mind-body connection.
The team note that problems with interleukin-33 could contribute to poor outcomes after spine or brain injuries adding, that it’s possible that if there’s some problem with this molecule in patients, they will have poor alarm signaling, and they will have very poor outcomes.
The team summise that the discovery also sheds light on previous findings connecting interleukin-33 to Alzheimer’s disease. Researchers have identified a strong connection between interleukin-33 and Alzheimer’s disease, and the current study will pave the way for future studies on this topic.
Eventually, the findings could lead to both improved treatments and new diagnostic tests for brain and spinal cord injury, Alzheimer’s and other conditions.
Source: University of Virginia
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.